|Description:||Rabbit polyclonal antibody to APOA5.|
|Dilutions:||WB 1:500 - 1:2000, IHC 1:50 - 1:100|
|Immunogen:||Recombinant protein of human APOA5|
|Formulation:||PBS with 0.02% sodium azide, 50% glycerol, pH7.3.|
|Storage:||Store at -20℃. Avoid freeze / thaw cycles.|
Target (Information from UniProt)
|Function:||Minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. May also be associated with chylomicrons. Important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and a inhibitor of the hepatic VLDL-TG production rate (without affecting the VLDL-apoB production rate) (By similarity). Activates poorly lecithin:cholesterol acyltransferase (LCAT) and does not enhance efflux of cholesterol from macrophages.|
|Tissue Specificity:||Liver and plasma.|
|Involvement in Disease:||Hypertriglyceridemia, familial: A common inherited disorder in which the concentration of very low density lipoprotein (VLDL) is elevated in the plasma. This leads to increased risk of heart disease, obesity, and pancreatitis.
Hyperlipoproteinemia 5: Characterized by increased amounts of chylomicrons and very low density lipoprotein (VLDL) and decreased low density lipoprotein (LDL) and high density lipoprotein (HDL) in the plasma after a fast. Numerous conditions cause this phenotype, including insulin-dependent diabetes mellitus, contraceptive steroids, alcohol abuse, and glycogen storage disease type 1A (GSD1A).
|Sequence Similarities:||Belongs to the apolipoprotein A1/A4/E family.|
|Post-Translational Modification:||Phosphorylated by FAM20C in the extracellular medium.|
Apolipoprotein A V Antibody
Apolipoprotein A-V Antibody
Apolipoprotein A5 Antibody
Regeneration associated protein 3 Antibody
Regeneration-associated protein 3 Antibody
Western blot analysis of extracts of Recombinant protein, using APOA5 antibody.
Immunohistochemistry of paraffin-embedded human liver using APOA5 antibody at dilution of 1:100 (40x lens).